ESR1 and neoplasm: Recent studies conducted in models of HER2+ breast tumors resistant to palbociclib plus anti-HER2 therapy and in tumor samples from patients with ER + /HER2- BC treated with ribociclib and endocrine therapy have suggested that intra-tumor heterogeneity might contribute to resistance14,23.